30-day money-back guarantee

Our Journey

We are VILIMED, a medical technology startup based in Lithuania, Northern Europe. We've developed the VILIM ball — a groundbreaking medical device designed to reduce hand tremors in people with Essential Tremor and Parkinson’s disease.

Built on years of research into how mechanical stimulation can affect the human nervous system, the VILIM ball represents a significant leap forward in tremor management.

Our Core Values

Our Promise of Care

Guided by honesty and compassion — we genuinely care about every story and are dedicated to helping people with Essential Tremor live with greater ease and dignity.

Integrity & Trust

Human-Centered Care

Innovative Science

We believe in what we do

“Although we’ve received awards both in Lithuania and internationally, and secured significant investment to grow our company, our greatest motivation comes from the heartfelt feedback we receive from our users. That’s the real driving force behind VILIMED’s growth and why we continue to improve the VILIM ball every day. Our hope is to one day offer a solution that helps everyone living with hand tremors.”

— Mantas Venslauskas, Co-founder and CEO of VILIMED

“We live in the 21‑st century—the age of AI, connected sensors, and chip‑scale miracles—yet much of healthcare is still running on yesterday’s tools. At Vilimed, we’re here to bridge that gap, one steady hand at a time. If our devices let someone sign their name or share a cup of coffee without tremor, the future is already arriving.”

— Edvinas Litvinas, Co-founder and CTO of VILIMED

“Science and technology are among the most powerful forces in the world, yet they're meaningless without the human ingenuity that transforms them into meaningful solutions. Alone, none of us could have created the Vilim Ball as it is today, but together we've developed a device capable of helping people reduce hand tremors and reclaim their independence.”

— Andrius Juknevičius, Co-founder and Senior Engineer of VILIMED

Our History

2018

VILIM ball successfully completed clinical trial

VILIM ball has successfully completed a clinical trial, demonstrating its safety, effectiveness, and potential benefits for users in managing hand tremors.

2019

Raised angel investment

VILIMED company successfully raised angel investment, securing early-stage funding to support product development, market entry, and business growth.

2020

Successful EN ISO 13485 certification

The company achieved successful EN ISO 13485 certification, demonstrating compliance with international quality management standards for medical devices and reinforcing its commitment to product safety and regulatory excellence.

2021

Received Class IIa CE mark certificate

The company received the Class IIa CE mark certificate, confirming that the device meets European Union standards for safety, health, and environmental protection, and is approved for sale within the EU as a compliant medical device.

2022

Start of trials with Parkinson’s patients, Secured VC investment 

The company has initiated clinical trials involving Parkinson’s patients to evaluate the effectiveness of the device in managing tremor symptoms and improving quality of life for individuals affected by the condition.  Also, we successfully secured venture capital investment, providing essential funding to accelerate product development, expand market reach, and support overall business growth.

2023

Launched Steady Hands app, Clinical evidence confirmed by post market data

We launched the Steady Hands app, a digital companion designed to support users in managing hand tremors through personalized tracking, progress monitoring, and integration with the VILIM ball device. Also in this year, Clinical evidence supporting the device’s effectiveness has been further validated by post-market data, demonstrating consistent real-world results and reinforcing its reliability and impact in everyday use.

2024

VILIM ball started to be reimbursed in Australia

VILIM ball has recently begun to be reimbursed in Australia and New Zealand, making it more accessible to patients through financial support from the healthcare system. Healthport International has been appointed as the official distributor, responsible for managing sales and distribution across the region.

Our partners